Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Virtual screening: are we there yet?

Mehran Jalaie1, Veerabahu Shanmugasundaram

  • 1Computer Assisted Drug Discovery, Pfizer Global Research & Development, Ann Arbor, Michigan 48105, USA. mehran.jalaie@pfizer.com

Mini Reviews in Medicinal Chemistry
|November 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor.

Journal of medicinal chemistry·2025
Same author

Comparative Analysis of Quantum-Mechanical and Standard Single-Structure Protein-Ligand Scoring Functions with MD-Based Free Energy Calculations.

Journal of chemical information and modeling·2025
Same author

Protein Frustration Reveals Active Sites in Co-Evolved GPCR:G Protein Complexes and in Engineered Targeted Degrader Complexes.

bioRxiv : the preprint server for biology·2025
Same author

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.

Cancer cell·2025
Same author

Leveraging efficiency metrics for the optimization of CELMoDs™ as cereblon-based molecular glue degraders.

RSC medicinal chemistry·2025
Same author

Insights from protein frustration analysis of BRD4-cereblon degrader ternary complexes show separation of strong from weak degraders.

RSC medicinal chemistry·2025
Same journal

PROTAC-Mediated Targeting of PARP via CRBN: Mechanistic Insights, Resistance Challenges, and Therapeutic Advancements.

Mini reviews in medicinal chemistry·2026
Same journal

Recent Advancements in the Development of Heterocyclic Scaffolds as Potential Anti-cancer Agents Targeting EGFR and VEGFR-2.

Mini reviews in medicinal chemistry·2026
Same journal

Exploring the Anticancer Potential of Synthetic β-Carboline Derivatives: A Comprehensive Systematic Review.

Mini reviews in medicinal chemistry·2026
Same journal

KIF20A in Human Malignancies: Oncogenic Mechanisms and Therapeutic Targeting Strategies.

Mini reviews in medicinal chemistry·2026
Same journal

Phytocompound-loaded Biomaterial-based Scaffolds: Emerging Strategies for Wound Healing Applications.

Mini reviews in medicinal chemistry·2026
Same journal

Bioprospecting of Natural Products as Sources of New Multitarget Therapies.

Mini reviews in medicinal chemistry·2026
See all related articles

Virtual screening (VS) accelerates drug discovery by analyzing compound databases computationally. This review explores VS strategies to identify drug candidates, aiding medicinal chemistry and complementing high-throughput screening (HTS).

Area of Science:

  • Drug Discovery and Development
  • Computational Chemistry
  • Pharmacology

Background:

  • Pharmaceutical development costs are rising, necessitating efficient methods to shorten timelines and reduce expenses.
  • Virtual screening (VS) has emerged as a key computational approach in early-stage drug discovery.
  • Numerous VS methodologies have been published, highlighting its growing importance.

Purpose of the Study:

  • To review various virtual screening (VS) approaches and strategies.
  • To identify compounds suitable for initiating medicinal chemistry campaigns.
  • To understand trends and drivers in VS to set realistic expectations for its application.

Main Methods:

  • Review of existing literature on virtual screening methodologies.

Related Experiment Videos

  • Analysis of different VS approaches and strategies employed in drug discovery.
  • Discussion on the integration of VS within broader screening campaigns.

    • Main Results:

    • Virtual screening is an integral part of early pharmaceutical discovery.
    • Various VS methods exist for identifying potential drug lead compounds.
    • Understanding VS capabilities and limitations is crucial for effective integration.

    Conclusions:

    • Virtual screening offers a cost-effective and time-efficient approach to drug discovery.
    • VS can be strategically integrated with experimental methods like high-throughput screening (HTS).
    • This review provides insights into optimizing VS for successful drug development campaigns.